Phaseline

Companies › Pyrotech Therapeutics

Pyrotech Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Other, Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PTT-121–Phase 1Healthy VollunteerAug 2027
PTT-936
Alpha Kinase 1 (ALPK1) activator
ALPK1Phase 1Locally Advanced or Metastatic Solid TumorsSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07768176PTT-121Phase 1Healthy VollunteerOtherAug 2027
NCT06244992PTT-936Phase 1Locally Advanced or Metastatic Solid TumorsOncologySep 2027

Targets

ALPK1 (1)

Companies with the same targets

Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.